Literature DB >> 9240421

Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology.

H Arai1, Y Morikawa, M Higuchi, T Matsui, C M Clark, M Miura, N Machida, V M Lee, J Q Trojanowski, H Sasaki.   

Abstract

Cerebrospinal fluid tau (CSF-tau) levels were quantified in 8 patients with frontotemporal dementia (FTD), 6 patients with progressive supranuclear palsy (PSP), 3 patients with corticobasal degeneration (CBD), and 6 patients with dementia with Lewy bodies (DLB). The CSF-tau levels were significantly increased in FTD and DLB, but not in PSP and CBD, compared to that previously reported in normal controls. Notably, the CSF-tau level in DLB was as high as that in Alzheimer's disease (AD). Our study suggests that tau may accumulate in the CSF of patients with certain neurodegenerative diseases other than AD and that measurement of CSF-tau may not distinguish AD from DLB.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9240421     DOI: 10.1006/bbrc.1997.6908

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

1.  Both total and phosphorylated tau are increased in Alzheimer's disease.

Authors:  M Sjögren; P Davidsson; M Tullberg; L Minthon; A Wallin; C Wikkelso; A K Granérus; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

2.  CSF biomarkers for Alzheimer's disease: current utility and potential future use.

Authors:  David M Holtzman
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

3.  Tau missing from CSF: a case report.

Authors:  Antonella Alberici; Mario Armani; Anna Paterlini; Luisa Benussi; Francesca Nicosia; Roberta Ghidoni; Simona Signorini; Maria Cotelli; Giovanni B Frisoni; Cristina Geroldi; Carlo P Trevisan; John H Growdon; Barbara Borroni; Alessandro Padovani; Paolo M Rossini; Giuliano Binetti
Journal:  J Neurol       Date:  2007-02-03       Impact factor: 4.849

4.  Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification.

Authors:  Hidenaga Yamamori; Sabiha Khatoon; Inge Grundke-Iqbal; Kaj Blennow; Michael Ewers; Harald Hampel; Khalid Iqbal
Journal:  Neurosci Lett       Date:  2007-03-14       Impact factor: 3.046

Review 5.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

6.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.

Authors:  M J de Leon; L Mosconi; J Li; S De Santi; Y Yao; W H Tsui; E Pirraglia; K Rich; E Javier; M Brys; L Glodzik; R Switalski; L A Saint Louis; D Pratico
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

Review 7.  [Dementia as a primary symptom in late onset multiple sclerosis. Case series and review of the literature].

Authors:  T Leyhe; C Laske; G Buchkremer; H Wormstall; H Wiendl
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

8.  CSF biomarkers in frontotemporal lobar degeneration with known pathology.

Authors:  H Bian; J C Van Swieten; S Leight; L Massimo; E Wood; M Forman; P Moore; I de Koning; C M Clark; S Rosso; J Trojanowski; V M-Y Lee; M Grossman
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

9.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

10.  Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies.

Authors:  Rachel Mistur; Lisa Mosconi; Susan De Santi; Marla Guzman; Yi Li; Wai Tsui; Mony J de Leon
Journal:  J Clin Neurol       Date:  2009-12-31       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.